Search Results for: alpha

New Alpha-Synuclein Therapy Begins Clinical Trial

Monday, 1 April 2019

The Parkinson’s therapeutic pipeline continues to grow as another therapy targeting the protein alpha-synuclein begins human studies. Earlier this month, BioArctic announced that it, along with its partner AbbVie, has begun clinical trials joining seven other alpha-synuclein therapies already being tested by…

Parkinson's research

Update on Alpha-synuclein Therapies in Clinical Trials

Monday, 17 July 2017

Last week biotech Prothena announced the first participant has enrolled in its PASADENA study, a Phase II trial of its anti-alpha-synuclein antibody therapy. Five companies have therapies in clinical trials targeting alpha-synuclein, the protein that clumps in the cells of people with…

Parkinson's Reseach at university of Queensland

Alpha-synuclein Research Progress for Parkinson’s

Saturday, 1 July 2017

As researchers search for a therapy to slow or stop Parkinson’s disease (PD) progression, alpha-synuclein has emerged as a leading target. This protein clumps in the brains of nearly everyone with Parkinson’s and it’s the primary component of Lewy bodies,…

Blood test may confirm parkinsons diagnosis

Alpha-synuclein Antibody moves a step closer

Monday, 14 November 2016

Therapeutic projects against top target protein alpha-synuclein continue to march through clinical testing and closer to patient hands. Yesterday biotechnology company Prothena announced results from its Phase Ib trial of PRX002, an antibody under investigation as a treatment to slow…

Another Piece of the Alpha-synuclein Puzzle Revealed

Monday, 25 July 2016

Research on alpha-synuclein, a lead target for therapy to slow or stop Parkinson’s and potential marker of disease progression, is quickly advancing, and scientists are learning more about this protein’s role in Parkinson’s disease (PD). Recently, researchers discovered how this…

Two More Alpha-synuclein Drugs in Clinical Trials

Monday, 17 August 2015

This week Michael J. Fox (MJFF)  funded biotech Neuropore Therapies announced the start of its Phase I trial of NPT200-11, a compound that binds to the protein alpha-synuclein to reduce its toxicity. Another company, Biogen, recently began a Phase I…

Who’s to Blame? Finding Toxic Alpha-synuclein

Monday, 28 April 2014

Alpha-synuclein shoulders a lot of blame in Parkinson’s disease (PD). This protein clumps in the cells of all Parkinson’s patients, leading to cell dysfunction and cell death. But not all alpha-synuclein may be bad. Scientists do not yet know the…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Study: Alpha-synuclein ‘Acts Like a Virus’

Saturday, 4 May 2013

Clumps of the protein alpha-synuclein are common to the brains of all people with Parkinson’s; unfortunately, there are more questions than answers as to whether and how alpha-synuclein plays a direct causative role in the disease. For this reason, scientists are investigating…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Alpha-Synuclein Imaging Consortium Publishes First Paper

Tuesday, 19 February 2013

Clumps of the protein alpha-synuclein accumulate in the brains of all people with Parkinson’s disease (PD). Finding ways to break up, clear, or eliminate the toxicity of these clumps could go a long way toward finding a disease-modifying treatment for…